The effect of tamoxifen on established human colorectal cancer cell lines in vitro. 1996

Y Ziv, and M K Gupta, and J W Milsom, and A Vladisavljevic, and K Kitago, and V W Fazio
Department of Colorectal Surgery, Assaf-Harofeh Medical Center, Zerifin, Israel.

The purpose of this study was to evaluate the effect of the anti-estrogenic tamoxifen (Tx) on the growth of human colorectal cancer cells. METHODS Serial concentrations (0.005 microM, 0.05 microM, 0.5 microM, 5 microM, and 50 microM) of the anti-estrogenic tamoxifen (Tx) were added and analyzed for their effect on the growth of established human colorectal cancer cells. HT-29 and SW-620 colon cancer cells and SW-1463 rectal cancer cells were tested in both serum-free media and serum-containing media (10% fetal calf serum). COLO-205 colon cancer and SW-837 rectal cancer cells were only tested in 10% fetal calf serum-containing media. Cell growth was measured with the hexosaminidase assay and was compared among the different groups. Cells were analyzed for estrogen receptors using enzyme immunoassay. RESULTS In serum-free media, Tx inhibited the growth of HT-29 (P = .05) and SW-620 (P = .01) colon cancer cells at all concentrations tested. RESULTS In serum-containing media, Tx inhibited (P = .04) the growth of the SW-837 rectal cancer cells at all concentrations and SW-1463 (P = .05) rectal cancer cells at the concentrations of 0.05 microM and 0.5 microM Tx. The inhibition of cell growth in HT-29, SW-620 and SW-1463 line was greater (P < .001) under serum-free media conditions. Estrogen receptors were not detected in any of the cell lines tested. CONCLUSIONS Hormonal manipulation with colo-rectal cancers is possible, but the effect of Tx on the growth of colon cancer cells differs from the effect on rectal cancer cells under various conditions. The mechanism of inhibition is not clear yet, and further studies are warranted before any clinical implications can be postulated.

UI MeSH Term Description Entries
D012004 Rectal Neoplasms Tumors or cancer of the RECTUM. Cancer of Rectum,Rectal Cancer,Rectal Tumors,Cancer of the Rectum,Neoplasms, Rectal,Rectum Cancer,Rectum Neoplasms,Cancer, Rectal,Cancer, Rectum,Neoplasm, Rectal,Neoplasm, Rectum,Rectal Cancers,Rectal Neoplasm,Rectal Tumor,Rectum Cancers,Rectum Neoplasm,Tumor, Rectal
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D004965 Estrogen Antagonists Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. Estradiol Antagonists,Antagonists, Estradiol,Antagonists, Estrogen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013629 Tamoxifen One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. ICI-46,474,ICI-46474,ICI-47699,Nolvadex,Novaldex,Soltamox,Tamoxifen Citrate,Tomaxithen,Zitazonium,Citrate, Tamoxifen,ICI 46,474,ICI 46474,ICI 47699,ICI46,474,ICI46474,ICI47699
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D018931 Antineoplastic Agents, Hormonal Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) Hormonal Antineoplastic Agents,Antineoplastic Drugs, Hormonal,Antineoplastic Hormonal Agents,Antineoplastic Hormonal Drugs,Antineoplastics, Hormonal,Hormonal Agents, Antineoplastic,Hormonal Antineoplastic Drugs,Hormonal Antineoplastics,Agents, Antineoplastic Hormonal,Drugs, Antineoplastic Hormonal,Hormonal Drugs, Antineoplastic

Related Publications

Y Ziv, and M K Gupta, and J W Milsom, and A Vladisavljevic, and K Kitago, and V W Fazio
June 1982, Cancer genetics and cytogenetics,
Y Ziv, and M K Gupta, and J W Milsom, and A Vladisavljevic, and K Kitago, and V W Fazio
October 1993, Zhonghua fu chan ke za zhi,
Y Ziv, and M K Gupta, and J W Milsom, and A Vladisavljevic, and K Kitago, and V W Fazio
June 1989, Cancer,
Y Ziv, and M K Gupta, and J W Milsom, and A Vladisavljevic, and K Kitago, and V W Fazio
December 1987, Cancer research,
Y Ziv, and M K Gupta, and J W Milsom, and A Vladisavljevic, and K Kitago, and V W Fazio
May 1966, Science (New York, N.Y.),
Y Ziv, and M K Gupta, and J W Milsom, and A Vladisavljevic, and K Kitago, and V W Fazio
April 1991, Proceedings of the National Science Council, Republic of China. Part B, Life sciences,
Y Ziv, and M K Gupta, and J W Milsom, and A Vladisavljevic, and K Kitago, and V W Fazio
April 1983, Experimental cell research,
Y Ziv, and M K Gupta, and J W Milsom, and A Vladisavljevic, and K Kitago, and V W Fazio
February 1983, Gan,
Y Ziv, and M K Gupta, and J W Milsom, and A Vladisavljevic, and K Kitago, and V W Fazio
September 1997, Proceedings of the National Academy of Sciences of the United States of America,
Y Ziv, and M K Gupta, and J W Milsom, and A Vladisavljevic, and K Kitago, and V W Fazio
September 1967, International journal of cancer,
Copied contents to your clipboard!